Simvastatin preserves diastolic function in experimental hypercholesterolemia independently of its lipid lowering effect

Atherosclerosis

Volumn 216, Issue 2, 2011, Pages 283-291

  Mannheim, Dallit ^a   Herrmann, Joerg ^a   Bonetti, Piero O ^b   Lavi, Ronit ^a   Lerman, Lilach O ^a   Lerman, Amir ^a  

^a MAYO CLINIC   (United States)

^b KANTONSSPITAL GRAUBÜNDEN   (Switzerland)

Author keywords

Angiogenesis; Diastolic dysfunction; Fibrosis; Hypercholesterolemia

Indexed keywords

COLLAGEN TYPE 3; LOW DENSITY LIPOPROTEIN; SIMVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DIASTOLIC BLOOD PRESSURE; DRUG DOSE INCREASE; DRUG EFFECT; EXPERIMENTAL PIG; FEMALE; HYPERCHOLESTEROLEMIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ANIMALS; DIASTOLE; DISEASE MODELS, ANIMAL; FEMALE; HEART FAILURE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYDROXYPROLINE; HYPERCHOLESTEROLEMIA; LIPIDS; MICROCIRCULATION; MICROVESSELS; MYOCARDIUM; SIMVASTATIN; SWINE; TOMOGRAPHY, X-RAY COMPUTED; X-RAY MICROTOMOGRAPHY;

EID: 79958002352     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.02.036     Document Type: Article

References (50)

1. Zile M.R., Brutsaert D.L. New concepts in diastolic dysfunction and diastolic heart failure: part I: diagnosis, prognosis, and measurements of diastolic function. Circulation 2002, 105:1387-1393.
2. Redfield M.M., Jacobsen S.J., Burnett J.C., Mahoney D.W., Bailey K.R., Rodeheffer R.J. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003, 289:194-202.
3. Zile M.R., Brutsaert D.L. New concepts in diastolic dysfunction and diastolic heart failure: part II: causal mechanisms and treatment. Circulation 2002, 105:1503-1508.
4. Brower G.L., Gardner J.D., Forman M.F., et al. The relationship between myocardial extracellular matrix remodeling and ventricular function. Eur J Cardiothorac Surg 2006, 30:604-610.
5. Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 2004, 63:423-432.
6. Paulus W.J. The role of nitric oxide in the failing heart. Heart Fail Rev 2001, 6:105-118.
7. Bonetti P.O., Lerman L.O., Napoli C., Lerman A. Statin effects beyond lipid lowering-are they clinically relevant?. Eur Heart J 2003, 24:225-248.
8. Takemoto M., Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001, 21:1712-1719.
9. Fukuta H., Sane D.C., Brucks S., Little W.C. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 2005, 112:357-363.
10. Shah R., Wang Y., Foody J.M. Effect of statins, angiotensin-converting enzyme inhibitors, and beta blockers on survival in patients ≥65 years of age with heart failure and preserved left ventricular systolic function. Am J Cardiol 2008, 101:217-222.
11. Herrmann J., Samee S., Chade A., Rodriguez Porcel M., Lerman L.O., Lerman A. Differential effect of experimental hypertension and hypercholesterolemia on adventitial remodeling. Arterioscler Thromb Vasc Biol 2005, 25:447-453.
12. Wilson S.H., Simari R.D., Best P.J., et al. Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering. Arterioscler Thromb Vasc Biol 2001, 21:122-128.
13. Wilson S.H., Herrmann J., Lerman L.O., et al. Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering. Circulation 2002, 105:415-418.
14. Bonetti P.O., Wilson S.H., Rodriguez-Porcel M., Holmes D.R., Lerman L.O., Lerman A. Simvastatin preserves myocardial perfusion and coronary microvascular permeability in experimental hypercholesterolemia independent of lipid lowering. J Am Coll Cardiol 2002, 40:546-554.
15. Rodriguez-Porcel M., Lerman A., Ritman E.L., Wilson S.H., Best P.J., Lerman L.O. Altered myocardial microvascular 3D architecture in experimental hypercholesterolemia. Circulation 2000, 102:2028-2030.
16. Rodriguez-Porcel M., Zhu X.Y., Chade A.R., et al. Functional and structural remodeling of the myocardial microvasculature in early experimental hypertension. Am J Physiol Heart Circ Physiol 2006, 290:H978-H984.
17. Zhu X.Y., Daghini E., Rodriguez-Porcel M., et al. Redox-sensitive myocardial remodeling and dysfunction in swine diet-induced experimental hypercholesterolemia. Atherosclerosis 2007, 193:62-69.
18. Rumberger J.A. Use of electron beam tomography to quantify cardiac diastolic function. Cardiol Clin 2000, 18:547-556.
19. Crisby M., Nordin-Fredriksson G., Shah P.K., Yano J., Zhu J., Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001, 103:926-933.
20. Stegemann H., Stalder K. Determination of hydroxyproline. Clin Chim Acta 1967, 18:267-273.
21. Miller E.J., Rhodes R.K. Preparation and characterization of the different types of collagen. Methods Enzymol 1982, 82(Pt A):33-64.
22. Mandinov L., Eberli F.R., Seiler C., Hess O.M. Diastolic heart failure. Cardiovasc Res 2000, 45:813-825.
23. Daghini E., Ritman E.L., Lerman L.O. Examine thy heart with all diligence: evaluation of cardiac function using fast computed tomography. Hypertension 2007, 49:249-256.
24. Thomson H.L., Basmadjian A.J., Rainbird A.J., et al. Contrast echocardiography improves the accuracy and reproducibility of left ventricular remodeling measurements: a prospective, randomly assigned, blinded study. J Am Coll Cardiol 2001, 38:867-875.
25. Rumberger J.A., Weiss R.M., Feiring A.J., et al. Patterns of regional diastolic function in the normal human left ventricle: an ultrafast computed tomographic study. J Am Coll Cardiol 1989, 14:119-126.
26. Lerman L.O., Siripornpitak S., Maffei N.L., Sheedy P.F., Ritman E.L. Measurement of in vivo myocardial microcirculatory function with electron beam CT. J Comput Assist Tomogr 1999, 23:390-398.
27. Daghini E., Primak A.N., Chade A.R., et al. Evaluation of porcine myocardial microvascular permeability and fractional vascular volume using 64-slice helical computed tomography (CT). Invest Radiol 2007, 42:274-282.
28. Palmiero P., Maiello M., Passantino A., et al. Correlation between diastolic impairment and lipid metabolism in mild-to-moderate hypertensive postmenopausal women. Am J Hypertens 2002, 15:615-620.
29. Salmasi A.M., Frost P., Dancy M. Impaired left ventricular diastolic function during isometric exercise in asymptomatic patients with hyperlipidaemia. Int J Cardiol 2004, 95:275-280.
30. Huang Y., Walker K.E., Hanley F., Narula J., Houser S.R., Tulenko T.N. Cardiac systolic and diastolic dysfunction after a cholesterol-rich diet. Circulation 2004, 109:97-102.
31. Norton G.R., Tsotetsi J., Trifunovic B., Hartford C., Candy G.P., Woodiwiss A.J. Myocardial stiffness is attributed to alterations in cross-linked collagen rather than total collagen or phenotypes in spontaneously hypertensive rats. Circulation 1997, 96:1991-1998.
32. Zhu X.Y., Daghini E., Chade A.R., et al. Simvastatin prevents coronary microvascular remodeling in renovascular hypertensive pigs. J Am Soc Nephrol 2007, 18:1209-1217.
33. Elesber A.A., Redfield M.M., Rihal C.S., et al. Coronary endothelial dysfunction and hyperlipidemia are independently associated with diastolic dysfunction in humans. Am Heart J 2007, 153:1081-1107.
34. Foody J.M., Shah R., Galusha D., Masoudi F.A., Havranek E.P., Krumholz H.M. Statins and mortality among elderly patients hospitalized with heart failure. Circulation 2006, 113:1086-1092.
35. Go A.S., Lee W.Y., Yang J., Lo J.C., Gurwitz J.H. Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA 2006, 296:2105-2111.
36. Ramasubbu K., Estep J., White D.L., Deswal A., Mann D.L. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol 2008, 51:415-426.
37. Pliquett R.U., Cornish K.G., Peuler J.D., Zucker I.H. Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation 2003, 107:2493-2498.
38. Pliquett R.U., Cornish K.G., Zucker I.H. Statin therapy restores sympathovagal balance in experimental heart failure. J Appl Physiol 2003, 95:700-704.
39. Gao L., Wang W., Li Y.L., et al. Simvastatin therapy normalizes sympathetic neural control in experimental heart failure: roles of angiotensin II type 1 receptors and NAD(P)H oxidase. Circulation 2005, 112:1763-1770.
40. Trochu J.N., Mital S., Zhang X., et al. Preservation of NO production by statins in the treatment of heart failure. Cardiovasc Res 2003, 60:250-258.
41. Greer J.J., Kakkar A.K., Elrod J.W., Watson L.J., Jones S.P., Lefer D.J. Low-dose simvastatin improves survival and ventricular function via eNOS in congestive heart failure. Am J Physiol Heart Circ Physiol 2006, 291:H2743-H2751.
42. Patel R., Nagueh S.F., Tsybouleva N., et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001, 104:317-324.
43. Hayashidani S., Tsutsui H., Shiomi T., et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002, 105:868-873.
44. Nakagami H., Jensen K.S., Liao J.K. A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mechanisms. Ann Med 2003, 35:398-403.
45. Zhu X.Y., Rodriguez-Porcel M., Bentley M.D., et al. Antioxidant intervention attenuates myocardial neovascularization in hypercholesterolemia. Circulation 2004, 109:2109-2115.
46. Wilson S.H., Chade A.R., Feldstein A., et al. Lipid-lowering-independent effects of simvastatin on the kidney in experimental hypercholesterolaemia. Nephrol Dial Transplant 2003, 18:703-709.
47. Boodhwani M., Nakai Y., Voisine P., et al. High-dose atorvastatin improves hypercholesterolemic coronary endothelial dysfunction without improving the angiogenic response. Circulation 2006, 114:I402-I408.
48. Dixon J.L., Shen S., Vuchetich J.P., Wysocka E., Sun G.Y., Sturek M. Increased atherosclerosis in diabetic dyslipidemic swine: protection by atorvastatin involves decreased VLDL triglycerides but minimal effects on the lipoprotein profile. J Lipid Res 2002, 43:1618-1629.
49. Hasler-Rapacz J., Kempen H.J., Princen H.M., Kudchodkar B.J., Lacko A., Rapacz J. Effects of simvastatin on plasma lipids and apolipoproteins in familial hypercholesterolemic swine. Arterioscler Thromb Vasc Biol 1996, 16:137-143.
50. Martinez-Gonzalez J., Alfon J., Berrozpe M., Badimon L. HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels. Atherosclerosis 2001, 159:27-33.